Department of Obstetrics and Gynecology, Ewha Womans University Seoul Hospital, College of Medicine, Ewha Womans University, Seoul, South Korea.
J Obstet Gynaecol Res. 2022 Jan;48(1):200-206. doi: 10.1111/jog.15076. Epub 2021 Oct 23.
To report our initial experience with robotic single-port myomectomy (RSPM) using the da Vinci SP surgical system and to evaluate the feasibility of the procedure.
This prospective observational study was performed at a university teaching hospital from January 2019 to December 2019. Sixty-one women with symptomatic fibroids received RSPM.
Based on seven resected fibroids and a maximal diameter of resected fibroids <10 cm, the women were arbitrarily divided into two groups. The mean number and maximal diameter of the removed fibroids were 3.7 ± 3.8 (2.3 ± 1.8 in Group 1 vs. 7.2 ± 5.3 in Group 2) and 7.6 ± 2.9 cm (6.8 ± 1.6 in Group 1 vs. 9.5 ± 4.3 in Group 2), respectively. The mean operation time, hemoglobin change, and hospital stay were 149.9 ± 72.9 min (123.8 ± 43.8 in Group 1 vs. 217.6 ± 89.4 in Group 2), 2.3 ± 1.0 g/dL (2.1 ± 0.9 in Group 1 vs. 2.7 ± 1.2 in Group 2), and 4.5 ± 0.8 days (4.4 ± 0.8 in Group 1 vs. 4.7 ± 0.9 in Group 2). There was no conversion to multi-port laparoscopy or laparotomy nor were there any major complications.
RSPM using the da Vinci SP surgical system is feasible surgical modality for women with symptomatic fibroid and is expected to increase indications of single-port myomectomy by solving many of the ergonomics problems inevitably accompanying single-port laparoscopic myomectomy.
报告我们使用达芬奇 SP 手术系统进行机器人单孔子宫肌瘤切除术(RSPM)的初步经验,并评估该手术的可行性。
这是一项前瞻性观察研究,于 2019 年 1 月至 2019 年 12 月在一所大学教学医院进行。61 名有症状的子宫肌瘤患者接受了 RSPM。
根据切除的 7 个肌瘤和最大直径<10cm 的肌瘤,将患者任意分为两组。切除肌瘤的平均数量和最大直径分别为 3.7±3.8(2.3±1.8 在组 1 中,7.2±5.3 在组 2 中)和 7.6±2.9cm(6.8±1.6 在组 1 中,9.5±4.3 在组 2 中)。平均手术时间、血红蛋白变化和住院时间分别为 149.9±72.9min(123.8±43.8 在组 1 中,217.6±89.4 在组 2 中)、2.3±1.0g/dL(2.1±0.9 在组 1 中,2.7±1.2 在组 2 中)和 4.5±0.8 天(4.4±0.8 在组 1 中,4.7±0.9 在组 2 中)。没有转为多孔腹腔镜或剖腹手术,也没有发生重大并发症。
使用达芬奇 SP 手术系统的 RSPM 是一种可行的手术方式,适用于有症状的子宫肌瘤患者,预计通过解决单孔腹腔镜子宫肌瘤切除术不可避免的许多人体工程学问题,增加单孔子宫肌瘤切除术的适应证。